Key Insights on Gross Profit: BioMarin Pharmaceutical Inc. vs Walgreens Boots Alliance, Inc.

BioMarin vs. Walgreens: A Decade of Financial Evolution

__timestampBioMarin Pharmaceutical Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 201462127600021569000000
Thursday, January 1, 201573788700026753000000
Friday, January 1, 201690723400029874000000
Sunday, January 1, 2017107186000029162000000
Monday, January 1, 2018117594800030792000000
Tuesday, January 1, 2019134458200028159000000
Wednesday, January 1, 2020133618300026077000000
Friday, January 1, 2021137576000028067000000
Saturday, January 1, 2022161237000028266000000
Sunday, January 1, 2023184216100027072000000
Monday, January 1, 2024227368000026524000000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Giants: BioMarin vs. Walgreens Boots Alliance

In the ever-evolving landscape of the pharmaceutical and retail sectors, BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc. stand as titans with distinct trajectories. From 2014 to 2023, BioMarin's gross profit surged by nearly 200%, reflecting its robust growth in the biotech industry. In contrast, Walgreens Boots Alliance, a stalwart in retail pharmacy, maintained a steady gross profit, peaking in 2018 with a 43% increase from 2014, before experiencing a slight decline.

BioMarin's consistent upward trend underscores its innovative edge in rare disease treatments, while Walgreens' performance highlights the challenges faced by traditional retail amidst digital transformation. Notably, 2024 data for BioMarin is absent, leaving room for speculation on its future trajectory. As these companies navigate their respective markets, their financial narratives offer valuable insights into industry dynamics and strategic positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025